Wall Street Zen Upgrades Sunshine Biopharma (NASDAQ:SBFM) to “Hold”

by · The Cerbat Gem

Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings upgraded shares of Sunshine Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Reduce”.

Get Our Latest Research Report on SBFM

Sunshine Biopharma Price Performance

Shares of NASDAQ SBFM opened at $2.93 on Friday. The firm’s 50-day moving average price is $14.16 and its 200-day moving average price is $109.35. Sunshine Biopharma has a 52-week low of $2.58 and a 52-week high of $464.00. The company has a market cap of $644,600.00, a PE ratio of -0.01 and a beta of 1.33.

Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($23.00) earnings per share for the quarter, topping the consensus estimate of ($24.00) by $1.00. Sunshine Biopharma had a negative net margin of 17.94% and a negative return on equity of 26.36%. The business had revenue of $9.26 million for the quarter, compared to analysts’ expectations of $8.70 million. As a group, equities research analysts anticipate that Sunshine Biopharma will post -39.00 EPS for the current fiscal year.

About Sunshine Biopharma

(Get Free Report)

Sunshine Biopharma, Inc is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors.

In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations.

Recommended Stories